CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 420 filers reported holding CRISPR THERAPEUTICS AG in Q2 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4,698,707 | -2.0% | 103,521 | +21.5% | 0.01% | -22.2% |
Q2 2023 | $4,794,872 | +24.7% | 85,221 | +0.2% | 0.01% | +28.6% |
Q1 2023 | $3,844,819 | +37.2% | 85,030 | +23.4% | 0.01% | +16.7% |
Q4 2022 | $2,802,163 | -16.0% | 68,915 | +35.0% | 0.01% | -25.0% |
Q3 2022 | $3,335,000 | +6.8% | 51,049 | +0.2% | 0.01% | +14.3% |
Q2 2022 | $3,123,000 | +1.8% | 50,930 | -1.2% | 0.01% | +16.7% |
Q1 2022 | $3,068,000 | -16.3% | 51,560 | +7.2% | 0.01% | -14.3% |
Q4 2021 | $3,664,000 | -22.0% | 48,099 | +14.6% | 0.01% | -30.0% |
Q3 2021 | $4,697,000 | -16.8% | 41,983 | +20.1% | 0.01% | -16.7% |
Q2 2021 | $5,645,000 | +54.5% | 34,963 | +16.4% | 0.01% | +33.3% |
Q1 2021 | $3,654,000 | +35.8% | 30,043 | +71.0% | 0.01% | +28.6% |
Q4 2020 | $2,691,000 | +48.7% | 17,567 | -18.9% | 0.01% | +40.0% |
Q3 2020 | $1,810,000 | +27.0% | 21,670 | +11.7% | 0.01% | 0.0% |
Q2 2020 | $1,425,000 | +73.6% | 19,399 | +1.2% | 0.01% | +66.7% |
Q1 2020 | $821,000 | – | 19,177 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |